Robeco Institutional Asset Management B.V. Has $114.07 Million Stock Holdings in Eli Lilly And Co (NYSE:LLY)

Robeco Institutional Asset Management B.V. boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 28.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,029,563 shares of the company’s stock after purchasing an additional 231,072 shares during the period. Robeco Institutional Asset Management B.V. owned 0.11% of Eli Lilly And Co worth $114,066,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Eli Lilly And Co in the fourth quarter valued at approximately $1,056,086,000. FMR LLC lifted its position in shares of Eli Lilly And Co by 83.9% in the fourth quarter. FMR LLC now owns 13,687,081 shares of the company’s stock valued at $1,583,870,000 after buying an additional 6,242,865 shares during the last quarter. Thoroughbred Financial Services LLC lifted its position in shares of Eli Lilly And Co by 11,124.4% in the second quarter. Thoroughbred Financial Services LLC now owns 854,403 shares of the company’s stock valued at $85,440,000 after buying an additional 846,791 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Eli Lilly And Co by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock valued at $1,514,582,000 after buying an additional 830,689 shares during the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of Eli Lilly And Co by 2,354.5% in the second quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after buying an additional 546,307 shares during the last quarter. 79.50% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the transaction, the vice president now directly owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Christi Shaw sold 7,577 shares of Eli Lilly And Co stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $117.14, for a total value of $887,569.78. Following the completion of the transaction, the senior vice president now directly owns 500 shares of the company’s stock, valued at $58,570. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by insiders.

Shares of NYSE LLY traded up $0.68 during mid-day trading on Wednesday, hitting $109.37. 3,874,754 shares of the stock traded hands, compared to its average volume of 3,629,401. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a twelve month low of $97.53 and a twelve month high of $132.13. The firm has a market capitalization of $105.11 billion, a P/E ratio of 19.71, a PEG ratio of 1.92 and a beta of 0.20. The firm’s 50 day simple moving average is $111.20.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The company had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the business posted $1.48 EPS. Eli Lilly And Co’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.36%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s payout ratio is presently 46.49%.

A number of analysts have recently issued reports on the company. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. TheStreet cut Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. Guggenheim cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price objective for the company. in a research report on Thursday, April 11th. Finally, BMO Capital Markets increased their target price on Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $123.49.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Forex

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.